Vascular Biology |
From the Department of Medical Biochemistry (L.W., M.I., H.N., R.C., J.S., M.H.), Ehime University School of Medicine, Ehime, Japan; the Department of Geriatric Medicine (M.A.), Kyorin University School of Medicine, Tokyo, Japan; and MG Consulting Co (M.d.G.), Rossemaison, Switzerland.
Correspondence to Masatsugu Horiuchi, MD, PhD, Department of Medical Biochemistry, Ehime University School of Medicine, Shigenobu, Onsen-gun, Ehime 791-0295, Japan. E-mail horiuchi{at}m.ehime-u.ac.jp
To clarify the possible involvement of uninhibited angiotensin II (Ang II) type 2 (AT2) receptor stimulation in the effects of an Ang II type 1 (AT1) receptor blocker, valsartan, we examined the cardiovascular remodeling induced by aortic banding with the use of wild-type (Agtr2+) and AT2 receptor null (Agtr2-) mice. Aortic banding caused cardiac hypertrophy in Agtr2+ and Agtr2- mice to a similar degree 6 weeks after surgery, whereas coronary arterial thickening and perivascular fibrosis were more exaggerated in Agtr2- mice. The AT2 receptor was observed predominantly in the coronary arteries and perivascular region of Agtr2+ mice. Valsartan at a dose of 1 mg/kg per day, which did not influence systolic blood pressure, suppressed cardiac hypertrophy similarly in both strains. Valsartan inhibited coronary arterial thickening and perivascular fibrosis in both groups; however, the inhibitory effects of valsartan were significantly weaker in Agtr2- mice. The inhibitory effects of a nonselective Ang II receptor antagonist, [Sar1,Ile8]-Ang II, on cardiac hypertrophy, coronary artery thickening, and perivascular fibrosis were not significantly different in Agtr2+ and Agtr2- mice. These results suggest that the improvement by valsartan of coronary arterial thickening and perivascular fibrosis after pressure overload is caused by uninhibited AT2 receptor stimulation in addition to AT1 receptor blockade.
Key Words: angiotensin receptors cardiomyocytes fibrosis coronary arteries
This article has been cited by other articles:
![]() |
T. Sawada, H. Yamada, B. Dahlof, H. Matsubara, and for the KYOTO HEART Study Group Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study Eur. Heart J., October 2, 2009; 30(20): 2461 - 2469. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-H. Jung, K. Chu, S.-T. Lee, S.-J. Kim, E.-C. Song, E.-H. Kim, D.-K. Park, D.-I. Sinn, J.-M. Kim, M. Kim, et al. Blockade of AT1 Receptor Reduces Apoptosis, Inflammation, and Oxidative Stress in Normotensive Rats with Intracerebral Hemorrhage J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1051 - 1058. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Voros, Z. Yang, C. M. Bove, W. D. Gilson, F. H. Epstein, B. A. French, S. S. Berr, S. P. Bishop, M. R. Conaway, H. Matsubara, et al. Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1004 - H1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. Sales, G. K. Sukhova, M. A. Lopez-Ilasaca, P. Libby, V. J. Dzau, and R. E. Pratt Angiotensin Type 2 Receptor Is Expressed in Murine Atherosclerotic Lesions and Modulates Lesion Evolution Circulation, November 22, 2005; 112(21): 3328 - 3336. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Iwai, R. Chen, Z. Li, T. Shiuchi, J. Suzuki, A. Ide, M. Tsuda, M. Okumura, L.-J. Min, M. Mogi, et al. Deletion of Angiotensin II Type 2 Receptor Exaggerated Atherosclerosis in Apolipoprotein E-Null Mice Circulation, September 13, 2005; 112(11): 1636 - 1643. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chen, J. L. Mehta, D. Li, L. Joseph, and J. Joseph Transforming Growth Factor {beta} Receptor Endoglin Is Expressed in Cardiac Fibroblasts and Modulates Profibrogenic Actions of Angiotensin II Circ. Res., December 10, 2004; 95(12): 1167 - 1173. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Iwai, H.-W. Liu, R. Chen, A. Ide, S. Okamoto, R. Hata, M. Sakanaka, T. Shiuchi, and M. Horiuchi Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor Stimulation Circulation, August 17, 2004; 110(7): 843 - 848. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Lako-Futo, I. Szokodi, B. Sarman, G. Foldes, H. Tokola, M. Ilves, H. Leskinen, O. Vuolteenaho, R. Skoumal, R. deChatel, et al. Evidence for a Functional Role of Angiotensin II Type 2 Receptor in the Cardiac Hypertrophic Process In Vivo in the Rat Heart Circulation, November 11, 2003; 108(19): 2414 - 2422. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Tian, J. Liu, P. Bitterman, and R. J. Bache Angiotensin II modulates nitric oxide-induced cardiac fibroblast apoptosis by activation of AKT/PKB Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1105 - H1112. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Xu, O. A. Carretero, Y.-H. Liu, E. G. Shesely, F. Yang, A. Kapke, and X.-P. Yang Role of AT2 Receptors in the Cardioprotective Effect of AT1 Antagonists in Mice Hypertension, September 1, 2002; 40(3): 244 - 250. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |